Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Rashe L, Kapp M, Einsele H, Mielke S (2014) EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant 49:163–167

  2. 2.

    Loren AW, Porter DL, Stadtmauer EA, Tsai DE (2003) Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 31:145–155

  3. 3.

    Dierickx D, Habermann TM (2018) Post-transplantation lymphoproliferative disorders in adults. N Engl J Med 378:549–562

  4. 4.

    Soiffer RJ (2019) Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 54:798–802

  5. 5.

    Merryman RW, Kim HT, Zinzani PL, Cario-Stella C, Ansell SM, Perales MA et al (2017) Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 129:1380–1388

  6. 6.

    Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 129:2471–2478

  7. 7.

    Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M et al (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Bio Blood Marrow Transplant 25:94–99

  8. 8.

    Kassa C, Remenyi P, Sinko J, Kallay K, Kertesz G, Kricvan G (2018) Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder. Pediatr Transplant 22:e13302

Download references

Acknowledgments

We are grateful to the medical, nursing, and laboratory staff of the participating departments for their contributions to this study.

Author information

Correspondence to Tadakazu Kondo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Statement of informed consent

Informed consent was obtained from the patient included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wada, F., Kondo, T., Nakamura, M. et al. Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab. Ann Hematol (2020). https://doi.org/10.1007/s00277-020-03960-4

Download citation